This article first appeared on GuruFocus .
-
Order Intake:Increased by 3.1% to CHF370.6 million.
-
Order Backlog:Increased to CHF346 million.
-
Net Sales:Declined by 7.7% to CHF333 million.
-
EBITDA:CHF38.6 million with a margin of 11.6%.
-
Net Profit:CHF17.6 million.
-
Dividend Proposal:CHF0.22 per share, payout ratio of 30%.
-
Investments:Total investments amounted to CHF45.9 million.
-
Cash Flow:Operating cash flow increased to CHF64.1 million.
-
Net Debt:CHF37.4 million, net debt/EBITDA ratio of 0.97.
-
Equity Ratio:26.5%.
-
Services and Consumables Sales:Increased by almost 29% to CHF116.5 million.
-
Equipment and Solutions Sales:Declined by 20% to CHF216.8 million.
-
Warning! GuruFocus has detected 4 Warning Sign with XSWX:SKAN.
-
Is XSWX:SKAN fairly valued? Test your thesis with our free DCF calculator.
Release Date: March 24, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
SKAN Group AG ( XSWX:SKAN ) reported a solid order intake of CHF370.6 million, indicating strong demand, particularly in Europe.
-
The company maintained a strong position in the high-end segment with a success rate of around 50% on submitted orders and realized projects.
-
Strategic acquisitions of Metronik and ABC Transfer expanded SKAN's portfolio, enhancing its position in the higher-margin service and consumables business.
-
The Services and Consumables segment showed robust performance with a 29% increase in net sales, driven by an expanding installed base and retrofit business.
-
SKAN Group AG continues to invest in innovation and strategic initiatives, such as pre-approved services and eBeam technology, to drive future growth.
Negative Points
-
Net sales declined by 7.7% to CHF333 million due to project postponements, particularly in vaccine lines.
-
EBITDA and EBITDA margin decreased, with EBITDA amounting to CHF38.6 million and a margin of 11.6%, impacted by lower net sales.
-
The US market showed cautiousness, affecting order intake and decision cycles, although there are signs of improvement.
-
A portion of the order backlog, around CHF15 million to CHF20 million, is subject to potential cancellation risk.
-
The pre-approved services project faced delays due to higher complexity in digitalization and automation, although the commercial launch is still planned for the second half of 2026.
Q & A Highlights
Q: Where does SKAN Group AG stand on the execution of projects postponed last year, and has the situation in the US normalized? A: Jonas Greutert, CEO, noted that the cautiousness in the US market has improved, with more project discussions and orders. Burim Maraj, CFO, added that significant progress has been made on postponed vaccine line projects, with revenue recognition expected in 2026 and some shifting to 2027.
Q: Can you split the successful quotation rate between Europe and the Americas? A: Burim Maraj, CFO, stated that the success rate in Europe was significantly higher than in the US, where cautiousness in decision-making was observed. However, there is now a rebound in US activity compared to Q4 2025.
Q: What was the acquisition impact for 2025, and should it be pro rata calculated for 2026? A: Burim Maraj, CFO, explained that the impact was mainly in the Services and Consumables business, with CHF60 million in net sales and a single-digit margin impact. The acquisitions were consolidated from August 2025, and growth is expected in 2026.
Q: What level of CapEx can be expected for the coming years? A: Burim Maraj, CFO, mentioned that CapEx will remain at a mid-single-digit level of net sales, primarily due to the completion of pre-approved services and the construction of a logistics hub.
Q: How much conservatism is in the 2026 guidance? A: Jonas Greutert, CEO, emphasized that the guidance is their best estimate for the year, with some unknowns. They aim to avoid repeating last year's guidance miss.
Q: Does the 2026 guidance account for the CHF15 million to CHF20 million cancellation risk? A: Burim Maraj, CFO, clarified that the guidance does not include this order, so any realization would be an upside.
Q: What gives confidence in maintaining the midterm guidance? A: Jonas Greutert, CEO, highlighted strong resources, a robust pipeline, and growth in Services and Consumables as factors supporting confidence in midterm guidance.
Q: How is CapEx evolving in the US, particularly regarding assembly lines? A: Burim Maraj, CFO, stated that current capacity in Germany and Switzerland is sufficient until 2029, so there is no immediate need for US assembly expansion.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
